Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
Sun Pharma's Halol plant gets 8 USFDA observations post inspection
Drug major Sun Pharma on Saturday said the US health regulator has issued a Form 483 with 8 observations after inspecting its Halol (Gujarat) manufacturing plant.
Texas governor signs bill allocating up to $100 million in funding for psychedelics research
Abbott's signing of Senate Bill 2308 comes as the governor faces political pressure from veterans groups to veto the state's proposed THC (Tetrahydrocannabinol) ban.
Fractyl Health to Present New Preclinical Data
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
WARRINGTON, Pa., Windtree Therapeutics, Inc., a diversified company focused on revenue generation
Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’
Questions remain as to how FDA inspection differences between domestic and foreign drug facilities will play out.
Gilead hit with FDA clinical hold for batch of HIV trials
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipel...
NHS to receive £29bn funding boost
The UK Government’s new investment includes funding for GP training and a £10bn outlay on technology and digital transformation.
Pancreatic cancer vaccines eliminate disease in preclinical trials
CLEVELAND—Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society.
MSD receives FDA approval for Enflonsia to prevent respiratory syncytial virus (RSV)
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in...
Aytu BioPharma to commercialise Exxua for major depressive disorder in the US
Aytu BioPharma to commercialise Exxua for major depressive disorder in the US
Psilera Collaborates with Drug Development Leader Hesperos
Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
26
27
28
29
30
31
32
33
34
